ABIONYX Pharma SA reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 5.3 million compared to EUR 0.7 million a year ago. Net loss was EUR 4.2 million compared to EUR 5.8 million a year ago.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.302 EUR | +1.09% |
|
+3.83% | +1.09% |
Jun. 14 | Abionyx: positive response from FDA, share price rises | CF |
Jun. 13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.09% | 44.55M | |
+14.84% | 121B | |
+18.31% | 112B | |
+4.51% | 22.57B | |
-18.26% | 20.82B | |
-14.23% | 16.3B | |
-16.50% | 16.19B | |
-42.36% | 16.17B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2022